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Paclitaxel, a powerful anti-neoplastic drug, often causes pathological pain, which significantly reduces the
quality of life in patients. Paclitaxel-induced pain includes pain that occurs immediately after paclitaxel treatment
(paclitaxel-associated acute pain syndrome, P-APS) and pain that persists for weeks to years after cessation of paclitaxel
treatment (paclitaxel induced chronic neuropathic pain). Mechanisms underlying P-APS remain unknown. In this study,
we found that paclitaxel causes acute pain in rodents in a dose-dependent manner. The paclitaxel-induced acute pain
occurs within 2 hrs after a single intravenous injection of paclitaxel. This is accompanied by low levels of paclitaxel
penetrating into the cerebral spinal fluid and spinal dorsal horn. We demonstrated that an intrathecal injection of
paclitaxel induces mechanical allodynia in a dose-dependent manner. Paclitaxel causes activation of toll like receptor
4 (TLR4) in the spinal dorsal horn and dorsal root ganglions. Through activating TLR4, paclitaxel increases glutamatergic
synaptic activities and reduces glial glutamate transporter activities in the dorsal horn. Activations of TLR4 are necessary
in the genesis of paclitaxel-induced acute pain. The cellular and molecular signaling pathways revealed in this study
could provide rationales for the development of analgesics and management strategies for P-APS in patients.
Keywords: Taxol, Nociception, DRG, Neuroinflammation, EPSC, Burrowing behaviorIntroduction
Paclitaxel (taxol) is a first-line chemotherapeutic-agent
used for the treatment of many types of cancers. Pa-
tients receiving taxol treatment often develop patho-
logical pain, which significantly reduces their quality of
life and hampers the use of this otherwise life-saving
chemotherapy in the clinic. Pathological pain induced by
taxol in patients includes pain that occurs immediately
after taxol treatment (known as paclitaxel-associated acute
pain syndrome, P-APS) [1,2], and pain that persists for
weeks to years after cessation of paclitaxel treatment
(known as paclitaxel induced chronic neuropathic pain)
[3,4]. P-APS is a significant morbidity in patients [1,2].
Currently, there is no proven standard of care for the pre-
vention or treatment of P-APS and mechanisms by which
paclitaxel induces P-APS are not known. The current un-
derstanding of mechanisms underlying taxol-induced
pathological pain in animal models is mainly based on
studies that examine pathological changes days after* Correspondence: hrweng@uga.edu
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unless otherwise stated.cessation of repeated taxol treatments. Little is known
about the direct and immediate action induced by taxol
on the pain signaling system in animal models.
It has been known since 1993 that treatment of pacli-
taxel can immediately induce pain symptom in patients
[5,6]. More recently such pain was defined as P-APS
[1,2]. P-APS is characterized by its early onset (occurring
within 1–3 days after drug administration) and short
lasting period (usually resolving within 7 days) [1,2]. To
date, no studies have been conducted to examine mech-
anisms related to the taxol induced acute pain in animal
models. Understanding such mechanisms could provide
rationales for the development of analgesics and treat-
ments for P-APS.
Paclitaxel has lipopolysaccharide (LPS)-mimetic activ-
ity causing the activation of toll like receptor 4 (TLR4)
and inducing the synthesis and release of several proin-
flammatory cytokines including tumor necrosis factor α
(TNFα) and interleukin-1β (IL-1β) in human monocytes,
T-lymphocytes, ovarian cancer cell lines [7], murine
peritoneal macrophages [8] and breast cancer cell lines
[9]. The increased synthesis and release of TNFα and
IL-1β is independent of the effects of taxol on microtubulesis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tor, expressed predominantly on microglia in the central
nervous system (CNS) [11,12]. Activation of TLR4 is critic-
ally implicated in the development and maintenance of
pathologic pain [13-15]. Paclitaxel is known for its poor
penetration into the CNS even though low concentrations
of paclitaxel in human cerebral spinal fluid (CSF) [16,17]
and rodent spinal cord [18] and brain [19,20] have been re-
peatedly demonstrated. It remains unexplored whether
traces of paclitaxel penetrating into the spinal cord produce
any functional impacts on the spinal pain signaling system.
Excessive activation of glutamate receptors in spinal
dorsal horn neurons is a hallmark mechanism of patho-
logical pain [21,22]. Activation of glutamate receptors is
governed by three key factors: the amount of glutamate
released from presynaptic terminals, the function and
number of postsynaptic glutamate receptors, and the
function of glutamate transporters. Since glutamate is
not metabolized extracellularly, the clearance of glutamate
released from presynaptic terminals and maintenance of
glutamate homeostasis depend on glutamate transporters
[21,23,24]. Glutamate transporters up-take glutamate into
the cell. Glial glutamate transporters account for more
than 90% of all CNS synaptic glutamate uptake [25] and
are a key part of the machinery for regulating synaptic
signal transmission [23]. Two types of glial glutamate
transporters [glial glutamate transporter 1 (GLT-1) and
glutamate aspartate transporter (GLAST)] are present
in the spinal dorsal horn [26,27]. We and others have
demonstrated that downregulation of astrocytic glutam-
ate transporter protein expression in the spinal dorsal
horn is associated with neuropathic pain (chronic allody-
nia) induced by repeated treatments of taxol [26,28] or
nerve injury [29-31]. It is unknown whether changes in
glutamate released from presynaptic terminals, postsynap-
tic glutamate receptors, and glial glutamate transporters
contribute to the development of paclitaxel-induced acute
pain.
In this study, we found that intravenous or intrathecal
administration of paclitaxel causes activation of TLR4 in
the spinal dorsal horn and dorsal root ganglions, and
TLR4 is required for paclitaxel to induce acute pain in
rodents. The direct impacts induced by paclitaxel on the
spinal glutamatergic synapses and glial glutamate trans-
porters were uncovered.
Results
Intravenous injection of paclitaxel induces acute pain in
rodents
To determine whether paclitaxel induces acute pain in
animals, nociceptive behaviors in rats were examined after
the rats were treated with paclitaxel or saline. Paclitaxel
(dose: 2 mg/kg; volume: 1 ml; duration of the injection:
1 min) was given to rats via the tail vein to simulateintravenous (i.v.) administration of taxol used in the clinic.
Vehicle control (1 ml) was injected into the rats in the
same fashion in the control group. A single i.v. injection
of taxol reduced thresholds of hind paw withdrawal re-
sponses to mechanical stimuli, which occurred within
2 hrs and peaked at 4 hrs but resolved within 24 hrs after
taxol injection (Figure 1A). Meanwhile, thresholds of hind
paw withdrawal responses to mechanical stimuli in rats
receiving vehicle (control group) remained unchanged.
This is in agreement with a previous report [32] showing
that a single intraperitoneal injection (i.p.) of paclitaxel
(1 mg/kg) in rats induces acute mechanical allodynia
between 1 and 6 hrs after paclitaxel treatment. Further-
more, we also determined the changes of mechanical
thresholds following i.v. paclitaxel injection at a higher
dose (5 mg/kg). Mechanical allodynia was observed within
1 hr, peaked between 4 to 6 hrs, lasted more than 48 hrs,
and ended before 72 hrs after paclitaxel injection
(Figure 1B), which lasts significantly longer than that
induced by paclitaxel at 2 mg/kg (Figure 1A). At the
same time period, mechanical thresholds in rats re-
ceiving vehicle were not significantly altered. These
data indicate that paclitaxel induces acute mechanical
allodynia in a dose-dependent manner.
Recent studies have demonstrated that innate burrowing
behavior can be used to measure the wellbeing of rodents.
When animals are in a status of pain, burrowing behavior
is reduced [33,34]. We then measured burrowing behav-
iors in rats treated with paclitaxel. After quantifying the
burrowing behavior at baseline, rats were divided into two
groups, one group receiving i.v. paclitaxel, the other re-
ceiving vehicle. We first determined burrowing behaviors
in rats receiving i.v. paclitaxel (2 mg/kg) or vehicle. As
mechanical allodynia induced by paclitaxel at this dose
peaked at 4 hrs and disappeared at 24 hrs after paclitaxel
injection, burrowing behaviors were measured at 4 and
24 hrs after the i.v. injection. In comparison with their
own baseline and their counterpart in the vehicle group,
the burrowing behaviors in the paclitaxel group were sig-
nificantly decreased at 4 hrs, but returned to baseline by
24 hrs (Figure 1C). When we measured burrowing behav-
iors in rats receiving paclitaxel at 5 mg/kg (i.v.), we found
that burrowing behaviors were significantly reduced at 4,
24, and 48 hrs, but recovered by 72 hrs after paclitaxel in-
jection (Figure 1D). Taking all data in Figure 1 together,
we conclude that paclitaxel induces acute pain in rats in a
dose-dependent manner.
Low levels of paclitaxel are found in the CSF and spinal
dorsal horn after paclitaxel injection and intrathecal
injection of paclitaxel induces acute pain in rats
To investigate whether paclitaxel penetration into the
spinal dorsal horn correlates to paclitaxel-induced acute
pain, paclitaxel concentrations in the CSF and spinal
Figure 1 (See legend on next page.)
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Figure 1 Paclitaxel induces acute mechanical allodynia and reduces burrowing activities. (A) and (B): Mechanical thresholds of withdrawal
responses in rats before (baseline) and at different time points after i.v. injection of paclitaxel at 2 mg/kg (A), 5 mg/kg (B), or vehicle are
plotted. (C) and (D): Burrowing activities in rats at different time points after i.v. injection of paclitaxel at 2 mg/kg (C), 5 mg/kg (D), or
vehicle are normalized to burrowing activities collected before the i.v. injection (baseline). Comparisons between baseline and at each time
point are indicated with ^ for the paclitaxel group. Comparisons between the vehicle group and the paclitaxel group at each time point are
labeled with #. One symbol: P < 0.05; Two symbols: P < 0.01; Three symbols: P < 0.001.
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24 hrs after i.v. injection of paclitaxel at 2 mg/kg) were an-
alyzed using liquid chromatography tandem mass spec-
trometry. The 2 and 4 hrs time points corresponded to
the time when allodynia occurred and the 24 hrs time
point corresponded to the time when allodynia disap-
peared (Figure 1A). Paclitaxel concentrations reached
mean levels of 1.85 to 2.70 ng/ml in the CSF (n = 7)
(Figure 2A) and 29.85 to 34.55 ng/g in the spinalFigure 2 Low levels of paclitaxel are found in the CSF and spinal dors
paclitaxel induces acute pain in rats. (A) and (B): Concentrations of paclit
i.v. injection of paclitaxel (2 mg/kg) are shown. Number of animals included in
(C): Mechanical thresholds of withdrawal responses in rats before (baseline) an
2 ng, and 20 ng, or vehicle in different groups are plotted. Comparisons betwe
2 ng paclitaxel, and with + for rats receiving 20 ng paclitaxel. Comparisons at e
paclitaxel are labeled with *, or rats receiving 20 ng paclitaxel are indicated witdorsal horn (n = 7) (Figure 2B) between 2 to 4 hrs after
paclitaxel injection. These paclitaxel concentrations went
down significantly to mean levels of 0.37 ng/ml in the CSF
(n = 7) and 11.67 ng/ml in the spinal dorsal horn (n = 7)
24 hrs after the injection. These concentrations are con-
sistent with data collected from human CSF [16,17], ro-
dent spinal cord [18] and mouse brains [19,20] sampled
within a similar time frame. Because the occurrence and
disappearance of acute pain behaviors coincided withal horn after paclitaxel injection and intrathecal injection of
axel in the CSF (A) and spinal dorsal horn (B) in rats at 2, 4, and 24 h after
each group for the analysis is shown in each bar. **P< 0.01; ***P< 0.001.
d different time points after intrathecal injection of paclitaxel at 0.2 ng,
en baseline and at each time point are indicated with ^ for rats receiving
ach time point between rats receiving vehicle, and rats receiving 2 ng
h #. One symbol: P< 0.05; Two symbols: P< 0.01.
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dorsal horn tissue, we proposed that paclitaxel in the CSF
and spinal dorsal horn may contribute to the development
of the paclitaxel induced acute pain. This was supported
by the following set of experiments. We injected paclitaxel
or vehicle (in a volume of 20 μl) directly into the intra-
thecal space through lumbar puncture in rats and exam-
ined the animal nociceptive behaviors. Three doses of
paclitaxel (0.2 ng, 2 ng, and 20 ng) were used. As shown
in Figure 2C, in comparison with rats injected with ve-
hicle, rats receiving paclitaxel developed mechanical allo-
dynia in a dose-dependent manner, which occurred within
30 min and disappeared at 2 hrs after the injection.
Activation of TLR4 in the spinal dorsal horn and dorsal
root ganglions is critically implicated in paclitaxel-induced
acute pain
It is known that paclitaxel has LPS-mimetic activity
causing activation of TLR4 [7,35,36], and activation of
TLR4 causes TLR4 tyrosine phosphorylation (p-TLR4)
[37,38]. Using Western blot, we determined if TLR4 re-
ceptors are activated following paclitaxel i.v. injection by
examining p-TLR4 levels in the spinal dorsal horn and
dorsal root ganglions at the L4-L5 segments. We found
that in comparison with rats treated with i.v. vehicle
injection, expressions of p-TLR4 in the spinal dorsal
horn and dorsal root ganglions were increased, whereas
total TLR4 (t-TLR4) remained unchanged 4 hrs after
i.v. injection of taxol (2 mg/kg) (Figure 3). We then
examined levels of p-TLR4 in the spinal dorsal horn
and dorsal root ganglions at the L4-L5 spinal segments in
rats 1 hr after paclitaxel (20 ng) or vehicle (in a volume of
20 μl) was injected into the intrathecal space throughFigure 3 TLR4 in the spinal dorsal horn and dorsal root ganglions are
paclitaxel. Expression of phosphorylated TLR4 (p-TLR4) and total TLR4 (t-TL
segments 4 hrs after i.v. injection of taxol (2 mg/kg) or vehicle are shown in
in the spinal dorsal horn and dorsal root ganglions of L4-L5 spinal segments
in (B). Number of animals included in each group for the analysis is indilumbar puncture. We found that in comparison with rats
receiving vehicle treatment, levels of p-TLR4 in the spinal
dorsal horn and dorsal root ganglions were increased in
rats treated with intrathecal (i.t.) injection of paclitaxel. At
the same time, no difference of t-TLR4 levels was found
between paclitaxel treated and vehicle-treated groups.
These data indicate that TLR4 at the spinal dorsal horn
and dorsal root ganglions is activated following i.v. or i.t.
injection of paclitaxel.
We next determined whether activation of TLR4 con-
tributes to the development of acute pain induced by
paclitaxel. Rats with pre-implanted intrathecal catheters
were randomly assigned into 4 groups: paclitaxel + i.t.
TLR4 antagonist group, paclitaxel + i.t. saline group, ve-
hicle + i.t. TLR4 antagonist group, and vehicle + i.t. saline
group. The TLR4 antagonist lipopolysaccharide-RS
(LPS-RS, 40 μg in a volume of 10 μl) was injected into
the rats through the implanted catheter immediately be-
fore and 3 hrs after the i.v. injection of taxol (2 mg/kg,
in a volume of 1 ml) in the paclitaxel + i.t. TLR4 antag-
onist group. The same type of LPS-RS treatment was ap-
plied to rats receiving the i.v. injection of vehicle (1 ml)
in the vehicle + i.t. TLR4 antagonist group. Intrathecal
injection of saline was applied to the rats in the pacli-
taxel + i.t. saline group and the vehicle + i.t. saline group
in the same fashion. The dose of LPS-RS was based on
previous studies [39-41]. As shown in Figure 4A, mech-
anical allodynia was basically abolished in the pacli-
taxel + i.t. TLR4 antagonist group in comparison with the
paclitaxel + i.t. saline group. Meanwhile nociceptive behav-
iors in the vehicle + i.t. TLR4 antagonist group, and ve-
hicle + i.t. saline group were not significantly altered
during the same observation period. These data indicateactivated following intravenous or intrathecal injection of
R4) in the spinal dorsal horn and dorsal root ganglions of L4-L5 spinal
(A). Expression of phosphorylated TLR4 (p-TLR4) and total TLR4 (t-TLR4)
1 hr after intrathecal injection of taxol (20 ng) or vehicle are shown
cated in each bar. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 4 Activation of TLR4 in the spinal dorsal horn is critically implicated in the paclitaxel-induced acute allodynia. (A): Line plots
show summaries of the mechanical thresholds of hind paw withdrawal responses (mean ± S.E.) in 4 groups of rats. Baseline indicates the baseline
measurement before animals received any treatments. Taxol (2 mg/kg) or vehicle was given to rats through the tail vein. LPS-RS or saline was
applied into the lumbar enlargement through an intrathecal catheter immediately before and at 3 h after i.v. injection of taxol or vehicle.
Comparisons between baseline and at each time point are indicated with v for the IV Taxol + IT saline group. Comparisons between the IV
Taxol + IT saline group and the IV Taxol + IT LPS-RS group are labeled with *. Comparisons between the IV Taxol + IT saline group and the IV
vehicle + IT LPS-RS group are labeled with #. Comparisons between the IV taxol + IT saline group and the IV vehicle + IT saline group are labeled
with +. (B): Line plots show summaries of the mechanical thresholds of hind paw withdrawal responses (mean ± S.E.) in 4 groups of mice. Taxol
(2 mg/kg) or vehicle was injected to mice intraperitoneally. Comparisons between baseline and at each time point are indicated with ^ for the
C57BL/6J (wild-type) + Taxol group. Comparisons between the C57BL/6J + Taxol group and the C57BL/6J + vehicle group are labeled with +.
Comparisons between the C57BL/6J + Taxol group and the TLR4 Knockout (KO) + taxol group are labeled with *. Comparisons between the TLR4
Knockout (KO) + vehicle group and the C57BL/6J+ taxol group are labeled with #. One symbol: P< 0.05; Two symbols: P< 0.01; Three symbols: P< 0.001.
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taxol induced acute pain.
To further confirm the role of TLR4 in paclitaxel-
induced acute pain, the effects of paclitaxel on nocicep-
tive behaviors in TLR4 knockout mice and wild-type
(C57BL/6J) mice were examined (Figure 4B). Similar to
those observed in rats (Figure 1), mechanical thresholds
of hind paw withdrawal responses in wild-type mice
began to drop within 2 hrs and peaked at 6 hrs and re-
solved by 24 hrs after receiving paclitaxel injection
(2 mg/kg, in a volume of 0.25 ml). Mechanical thresh-
olds in mice receiving vehicle treatments were not sig-
nificantly altered in the same period. Prior to any
treatments, TLR4 knockout mice had similar mechanicalthresholds as wild-type mice (Figure 4B). However, when
paclitaxel (2 mg/kg, in a volume of 0.25 ml) or vehicle
(0.25 ml) was i.p. injected to TLR4 knockout mice,
mechanical thresholds remained unchanged in both groups
(Figure 4B). These data further confirm our conclusion
that TLR4 is critically implicated in the paclitaxel-induced
acute pain.
Paclitaxel increases the release of glutamate from
presynaptic terminals and the activity of glutamate
receptors at postsynaptic neurons in the spinal dorsal
horn
We next investigated the direct impact, induced by acti-
vation of spinal TLR4 upon paclitaxel administration, on
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excessive activation of glutamatergic receptors in the
spinal dorsal horn is one of the most critical mecha-
nisms leading to abnormal neuronal activation in the
pain signaling pathway in pathological pain conditions
[24,42-44]. To study the direct action of paclitaxel on
glutamatergic synaptic activities in the spinal dorsal
horn, we determined the effects of paclitaxel on glutam-
ate release from presynaptic terminals and postsynaptic
glutamate receptor activities in the spinal dorsal horn.
Analysis of miniature excitatory postsynaptic currents
(mEPSCs) is a conventional approach to identify changes
of glutamatergic synapses at the pre- and post- synaptic
levels. An increase in mEPSC frequencies indicates an
increase in the presynaptic transmitter release probability,
whereas an increase in mEPSC amplitudes indicates an
increase in the post-synaptic receptor activities [45,46].
Neurons receiving monosynaptic input from peripheral
A and C fibers in the superficial spinal dorsal horn (lamina I
and outer lamina II) [44,47] were recorded. Glutamatergic
mEPSCs in dorsal horn neurons of rats and mice were
recorded before and after bath perfusion of paclitaxel
(1 ng/ml, the low end concentration of paclitaxel found in
the CSF 4 hrs after i.v. injection of taxol). Paclitaxel perfu-
sion significantly increased glutamatergic mEPSC frequen-
cies from 2.88 ± 0.08 to 6.14 ± 0.47 Hz (n = 15, P < 0.001)
and amplitudes from 26.32 ± 0.47 to 32.60 ± 0.71 pA
(n = 15, P < 0.001) in slices of rats (Figure 5A, and E).
Similarly, mEPSCs frequencies and amplitudes recorded
from mice were significantly increased (n = 10, P < 0.001)
after paclitaxel (1 ng/ml) was added into the bath
(Figure 5G). Furthermore, in the other 8 cells recorded
from rats, we examined their responses to paclitaxel per-
fusion at three concentrations (0.1 ng/ml, 1 ng/ml, and
10 ng/ml). As shown in Figure 5B and F, paclitaxel in-
creased the mEPSC frequencies and amplitudes in a
dose-dependent manner. These data indicate that the
paclitaxel-induced acute pain results, at least in part,
from increased release of glutamate from presynaptic
terminals, and increased postsynaptic glutamate recep-
tor functions in the spinal dorsal horn.
Frequencies and amplitudes of mEPSCs are increased by
paclitaxel in spinal dorsal horn neurons through
activation of TLR4
To determine whether activation of TLR4 is involved in the
increased glutamatergic synaptic activities induced by pacli-
taxel in the spinal dorsal horn, we recorded glutamatergic
mEPSCs from neurons that received monosynaptic input
from the primary afferents in the superficial spinal dorsal
horn in rats and mice. After recording baseline mEPSCs, we
bath-perfused the TLR4 antagonist (LPS-RS, 2 μg/ml).
LPS-RS did not change either mEPSC frequencies or
amplitudes in rats (Figure 5C and H) and mice (Figure 5I).In the presence of LPS-RS, further addition of paclitaxel
(1 ng/ml) did not induce changes in mEPSC frequencies
or amplitudes in rats (Figure 5C and H) and wild-type
mice (Figure 5I), which is in contrast with data collected
in the absence of LPS-RS. Further, when we recorded
mEPSCs from spinal slices obtained from TLR4 knockout
mice, mEPSC frequencies and amplitudes were not altered
by bath-application of paclitaxel (1 ng/ml) (Figure 5D
and J). These data indicate that glutamatergic synaptic
activities in normal conditions are not under the con-
trol of TLR4 activities, and paclitaxel increases the re-
lease of glutamate from presynaptic terminals and function
of glutamate receptors at the postsynaptic neurons in the
spinal dorsal horn through activation of TLR4.
Dysfunction of glial glutamate transporters (GTs)
contributes to the development of the paclitaxel-induced
acute pain
We previously demonstrated that the function of glu-
tamate transporters is a key factor regulating activation
of glutamate receptors in the spinal dorsal horn [48,49].
To determine if glutamate transporter functions are
altered by paclitaxel, we simulated the topical effects
induced by paclitaxel in the CSF on spinal glutamate
transporter activities in the intact spinal cord. After
exposing the L4-L5 spinal segments with the dura
open and the pia intact in anesthetized rats, we topic-
ally placed a piece of cotton, which was soaked with
taxol (concentration: 2 ng/ml) in artificial cerebro-
spinal fluid (aCSF) at 35°C, onto the L4-L5 region for
30 min. This taxol concentration is within the range
of taxol concentrations in the CSF and spinal dorsal
horn tissue in rats receiving taxol (2 mg/kg) injection
(Figure 2). Synaptosome preparations were prepared
from the L4-L5 spinal dorsal horn immediately after the
taxol treatment and incubated with [3H]L-glutamate. The
glutamate uptake was determined by measuring the radio-
activity of [3H]L-glutamate in the synaptosome prepara-
tions [50,51]. In comparison with the control (n = 4)
treated with vehicles, the synaptosome preparations ob-
tained from rats receiving the topical paclitaxel treatment
had a 14.95 ± 2.13% (n = 4. P < 0.01) reduction of glutam-
ate uptake activities (Figure 6A). These results indicate
that dysfunction of GTs in the spinal dorsal horn contrib-
utes to the development of paclitaxel-induced acute pain.
Further, these data also provide evidence that the reduc-
tion of glutamate uptake activities in the spinal dorsal
horn after paclitaxel i.v. injection is directly due to pacli-
taxel penetrating to the CSF and spinal cord tissue.
To determine mechanisms underlying the suppression
induced by taxol on glutamate uptake activities, we ana-
lyzed trafficking of glial GTs (GLT-1 and GLAST), be-
tween the plasma membrane and cytosol in rat spinal
slices of L4-L5 segments (400 μm thick) incubated for
Figure 5 (See legend on next page.)
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Figure 5 Paclitaxel increases the release of glutamate from presynaptic terminals and activities of glutamate receptors at postsynaptic
neurons in the spinal dorsal horn through activation of TLR4. Raw data show that bath-perfusion of paclitaxel significantly increased both
the frequency and amplitudes of mEPSCs in a dose-dependent manner in rats (A) and (B), but these effects were abolished in rats in the presence of
the TLR4 inhibitor (LPS-RS) (C), and in TLR4 knockout mice (D). Bar graphs show the mean (+ S.E.) frequency and amplitude of mEPSCs before, during,
and after washout of paclitaxel (1 ng/ml) in rats (E) and wild-type mice (G), as well as in the presence of LPS-RS in rats (H) and wild-type mice (I). The
mean (+ S.E.) frequency and amplitude of mEPSCs before, during, and after washout of paclitaxel at 0.1 ng/ml, 1 ng/ml, and 10 ng/ml in rats
are presented in (F). The mean (+ S.E.) frequency and amplitude of mEPSCs before and during paclitaxel (1 ng/ml) perfusion in TLR4 knockout
mice are shown in (J). Number of neurons included in each group for the analysis is shown in each bar. **P < 0.01; ***P < 0.001; NS,
no statistical significance.
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vehicles. Compared to slices treated with vehicles, slices
treated with paclitaxel had decreased protein expressions
of GLT-1 and GLAST in the cell membrane but in-
creased expressions of GLT-1 and GLAST in the cytosol
(Figure 6B). The sum expression of GLT-1 in the mem-
brane and cytosol and the sum expression of GLAST in
the membrane and cytosol in the paclitaxel-treated slices
were similar to their counterparts in slices treated with
vehicles (n = 5; data not shown). These data indicate that
internalization of GLT-1 and GLAST in the spinal dorsal
horn is an important mechanism leading to a reduction
of glutamate uptake induced by paclitaxel.
Paclitaxel reduces glial glutamate transporter activities
through activating TLR4
To investigate how taxol suppresses glial glutamate trans-
porter activities, we monitored glial glutamate transporter
activities in real time by recording glutamate transporter
currents (GTCs) from astrocytes. The uptake of glutamate
by glial glutamate transporters is accompanied by the
co-transport of two or three Na+ with one H+ and the
countertransport of one K+ [52-54]. Because of the trans-
location of a net positive charge during each transport
cycle, glutamate uptake generates a current called GTCFigure 6 Dysfunction of glial glutamate transporters contributes to the
show percentage changes of glutamate uptake in the spinal dorsal horn after
(B): Paclitaxel reduces GLT-1 and GLAST protein expressions in the cell surface
(membrane) and cytosol in spinal dorsal horn slices treated with paclitaxel an
relative density of GLT-1 and GLAST in the plasma membrane to EGFR, and t
to α-tubulin in each group. Number of animals included in each group[52-54]. The size of GTC reflects the amount of trans-
ported glutamate, which has been widely used as an ef-
fective tool to study the function of glial glutamate
transporters [51,55-57]. GTCs were recorded from spinal
slices of mice. Astrocytes were labeled by the astro-
cyte specific dye, sulforhodomine 101 (100 μM) [58]
(Figure 7A), which was pressure-injected into the
spinal slice through a pipette with a picospritzer [29,58,59].
The recorded cells displayed a linear IV relationship (a pas-
sive membrane property) (Figure 7B) and a low input re-
sistance (10–20 MΩ), a membrane property characteristic
of astrocytes. The accuracy of such techniques in iden-
tifying astrocytes was confirmed by single-cell RT-PCR
(Figure 7C) in 8 cells. All 8 cells identified using this
technique expressed the glial fibrillary acid protein
(GFAP), demonstrating the reliability of this technique.
GTCs were evoked by L-glutamate (50 μM) injected
onto the astrocyte through a puff-electrode [51]. Such
currents were almost abolished in the presence of the
specific glial glutamate transporter blocker TFB-TBOA
(10 μM) [60] (Figure 7D), confirming that these currents
were generated from glutamate transporter activities. We
found that perfusion of paclitaxel directly onto the recording
bath at a concentration as low as 1 ng/ml significantly re-
duced GTC amplitudes by 34.11 ± 4.42% (n = 10, P < 0.001)development of paclitaxel-induced acute allodynia. (A): Bar graphs
paclitaxel (2 ng/ml) was applied onto the intact spinal cord for 30 min.
. Samples of GLT-1 and GLAST protein expressions in the cell surface
d vehicle for 15 minutes are shown. Bar graphs show the mean (+S.E.)
he mean (+S.E.) relative density of GLT-1 and GLAST in the cytosol
for the analysis is shown in each bar. ***P < 0.001.
Figure 7 Paclitaxel reduces glial glutamate transporter activities through activating TLR4. (A): An astrocyte in the mouse spinal dorsal
horn was stained by the astrocyte specific dye, sulforhodomine 101 (SR101, 100 μM) (top). (B): Inward and outward currents (top) in a spinal
astrocyte were evoked by voltage steps (10 mV/step) from −130 mV to +70 mV (bottom), indicating a passive membrane property of astrocytes. (C):
Astrocytes identified by this way all (8 cells) expressed GFAP. N: Negative control. GAPDH was used as internal control. GTCs were evoked by L-glutamate
(50 μM) injected onto the astrocyte through a puff-electrode (A, bottom). Such currents were almost abolished in the presence of the specific glial glu-
tamate transporter blocker TFB-TBOA (10 μM) (D). Bath-perfusion of paclitaxel (1 ng/ml) significantly reduced GTC amplitudes and charge transfers (E),
and these effects were abolished in the presence of the TLR4 antagonist LPS-RS (2 μg/ml) (F). (G): GTCs recorded from spinal slices obtained
from TLR4 knockout mice were not altered by bath-perfusion of paclitaxel (1 ng/ml). Bar graphs show the mean (+S.E.) GTC amplitude and
charge transfer before (baseline), during and after washout of the tested agent(s). Number of animals included in each group for the ana-
lysis is shown in each bar. ***P < 0.001; NS, no statistical significance.
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(Figure 7E). These data confirm that glial glutamate trans-
porter activities are reduced by paclitaxel. We next deter-
mined whether TLR4 mediates the effects induced by
paclitaxel on GTCs. After recording baseline GTCs, we
bath-perfused the TLR4 antagonist (LPS-RS, 2 μg/ml).
Perfusion of LPS-RS did not induce changes in GTC
charge transfers and amplitudes, indicating that glial glu-
tamate transporter activities are not controlled by TLR4
activation under normal conditions. In the presence of
LPS-RS, further addition of paclitaxel (1 ng/ml) into the
recording bath did not alter GTC charge transfers and
amplitudes (Figure 7F). Furthermore, when we recorded
GTCs from spinal slices obtained from TLR4 knockout
mice, we found that GTCs remained unchanged after
bath-perfusion of paclitaxel (1 ng/ml) (Figure 7G). To-
gether, these data indicate that paclitaxel reduces glial glu-
tamate transporter activities through activating TLR4.
Discussion
Our study is the first to reveal that paclitaxel induces
acute pain through activating TLR4. Specifically, we
found that low levels of paclitaxel penetrates into the
CSF in rats receiving i.v. injection of paclitaxel. Intrathecal
injection of paclitaxel induces mechanical allodynia in a
dose-dependent manner. We also provide evidence that
paclitaxel induces activation of TLR4 in the spinal dorsal
horn and dorsal root ganglions. Activation of TLR4 by
paclitaxel increases glutamatergic synaptic activities and
reduces glial glutamate transporter activities. The cellular
and molecular signaling pathways revealed in this study
could provide strategies for the development of analgesics
and management of P-APS in patients.
Acute pain induced by paclitaxel treatment
P-APS is a significant morbidity in patients receiving pacli-
taxel treatment, with an incidence of 88% in patients treated
with paclitaxel at a dose of more than 175 mg/m2 in the first
cycle [1,2]. The pain in patients is most prominent in the
lower extremities [1,2]. P-APS in patients receiving paclitaxel
at a dose of more than 175 mg/m2 usually occurs within
1–3 days after drug administration and resolves within
7 days [1]. In this study, we found that paclitaxel induces
acute pain in rodents in a dose-dependent manner. The
onset and duration of acute pain in rodents are shorter
than those for P-APS in humans, which may reflect a dif-
ference in species and the low taxol doses used in this
study. Nevertheless, our data presents the first evidence for
the direct action by paclitaxel on spinal nociceptive sensory
processing. The doses of 2mg/kg (which equals 14.06mg/m2)
and 5 mg/kg (which equals 35.16 mg/m2) [61,62] used in this
study are moderate doses, which are within the dose range
widely used by many labs for the study of paclitaxel-induced
neuropathic pain in rodents [28,63-67]. Further, since the doseof taxol used in clinics ranges from 15 mg/m2 up to 825 mg/
m2 [68-72], the doses used in this study are a conservative
simulation of clinically relevant doses.
Paclitaxel penetrating into the spinal dorsal horn is a
critical event leading to the development of acute pain
following paclitaxel injection
Currently, mechanisms underlying P-APS remain un-
known. Our current study provides evidence that pacli-
taxel penetrating into the spinal dorsal horn contributes
to the development of acute pain following paclitaxel in-
jection in animals. Using liquid chromatography tandem
mass spectrometry, we, for the first time, show that rats
receiving a single i.v. paclitaxel (2 mg/kg) injection had
low levels of paclitaxel penetrating into the CSF and
spinal dorsal horn between 2 to 4 hrs after the paclitaxel
injection. These levels went down significantly at 24 hrs
post injection. These data are in agreement with previ-
ous studies in human cerebral spinal fluid and rodent
spinal cord and brain. For example, patients have pacli-
taxel levels in the CSF between 4.25 and 70.88 ng/ml at
3.25 to 5 hrs following intravenous injection of paclitaxel
(90–200 mg/m2) [16], and 2.98 to 49.01 ng/ml at 0.5 hr
after intravenous injection of paclitaxel (175 mg/m2)
[17]. Paclitaxel levels in the spinal cord of rats are between
5.9 to 17.3 ng/g on day 11 after rats receiving intravenous
application of paclitaxel 5 mg/kg/day on days 1, 2, 3, 9
and 10 [18]. Despite the existence of paclitaxel in the
CNS, no studies have been reported on the impact of
paclitaxel on CNS functions. Here, we demonstrated
that topical application of paclitaxel in the intrathecal
space induces mechanical allodynia in a dose-dependent
manner.
Among many factors leading to aberrant activation of
neurons in the pain signaling pathway, excessive activa-
tion of glutamate receptors in the spinal dorsal horn is a
key factor [21,22]. The activation of glutamate receptors
is determined by three essential factors: the amount of
synaptically released glutamate, the rate at which glu-
tamate is removed by glutamate transporters, and the
properties and number of postsynaptic glutamate recep-
tors [73,74]. Glial glutamate transporters account for
over 90% of all CNS synaptic glutamate uptake [25]. Our
present study found that paclitaxel in the spinal dorsal
horn can enhance glutamate receptor activation by alter-
ing all of these three factors. Paclitaxel at a concentra-
tion as low as 1 ng/ml (which is at the low end of the
paclitaxel concentration range found in the CSF 2 to
4 hrs after paclitaxel injection) significantly increases
glutamatergic synaptic activities by facilitating presynap-
tic glutamate release and increasing glutamate receptor
activities at the postsynaptic neurons in the spinal dorsal
horn (Figure 5). Paclitaxel at this concentration also sig-
nificantly reduced glial glutamate transporter activities
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found that topical application of paclitaxel (2 ng/ml) on
the surface of the intact spinal cord causes the reduction
of glutamate transporter activities in the spinal dorsal
horn (Figure 6). These findings indicate that paclitaxel
penetrating into the spinal dorsal horn and the subse-
quent enhanced activation of glutamate receptors as well
as the reduction of glial glutamate transporters play an
important role in the acute pain induced by paclitaxel.
Further studies are warranted to investigate how gluta-
matergic synaptic activities are enhanced by paclitaxel.Paclitaxel induces acute pain through activating TLR4
Numerous studies have shown that activation of TLR4 is
a critical component contributing to the genesis of
pathologic pain. For example, intrathecal or peritoneal
injection of the TLR4 agonist LPS induces allodynia in
mice [75] and rats [76,77]. Pharmacological blocking or
gene knockout of TLR4 attenuates both thermal and
mechanical allodynia in mice with neuropathic pain in-
duced by nerve injury, and prevents activation of the
transcription factor NF-kB and the over-production of
TNFα and IL-1β in the spinal cord [13-15]. Paclitaxel
has LPS-mimetic activity causing the activation of TLR4.
For example, exposing murine peritoneal macrophages
[8], breast cancer cell lines [9], and human monocytes
[7] to paclitaxel causes activation of TLR4 and release of
TNFα and IL-1β. Currently no studies have been re-
ported regarding the direct activation of TLR4 in the
nervous system by paclitaxel and its functional implica-
tions. We collected several lines of evidence supporting
the critical role of TLR4 activation in the genesis of pac-
litaxel induced acute pain: a). TLR4 in the spinal dorsal
horn and dorsal root ganglions is activated in animals
receiving paclitaxel at a dose that simulates the low end
of doses used clinically (Figure 3); b). the paclitaxel-
induced acute allodynia was abolished in TLR4 knockout
mice or by intrathecal injections of a TLR4 antagonist in
rats (Figure 4); c). TLR4 mediates the enhanced gluta-
matergic synaptic activities (Figure 5), as well as the re-
duced glial GT activities (Figure 7) induced by paclitaxel
in the spinal dorsal horn.Conclusions
Our study for the first time reveals a mechanism under-
lying paclitaxel induced acute pain in animals. We iden-
tify that activation of TLR4 in the spinal dorsal horn and
dorsal root ganglions, increased glutamatergic synaptic
activities, and reduced glial glutamate transporter activ-
ities in the spinal dorsal horn are critical events in the
genesis of the paclitaxel-induced acute pain in animals.
Thus, preventing or reversing these abnormalities could
potentially prevent and attenuate P-APS in patients.Methods and materials
Animals
Adult male (220 to 260 g) Sprague Dawley rats and 6–8
week old male wild-type mice (strain: C57BL/6J), and TLR4
knockout mice (Strain: B10scN-Tlr4lps-del/JthJ) were used.
All experiments were approved by the Institutional Animal
Care and Use Committee at the University of Georgia and
were fully compliant with the National Institutes of Health
Guidelines for the Use and Care of Laboratory Animals.
Drug administration
Paclitaxel (2 mg/kg, or 5 mg/kg) was injected into rats
through the tail vein to mimic the i.v. administration of
paclitaxel used in the clinic. Mice received paclitaxel
(2 mg/kg) through intraperitoneal (i.p.) injection. Pacli-
taxel (Taxol, Bristol-Myers Squib, 6 mg/ml in Cremo-
phor EL and dehydrated ethanol) was diluted with saline
to make up a volume of 1 ml for rats or 0.25 ml for mice
for injection. Vehicle was composed of the same amounts of
Cremophor EL and dehydrated ethanol (Sigma Chemicals,
St. Louis, MO, USA) diluted with saline to the same volume.
The experimenter was blind to the type of drugs injected to
the animal. Intrathecal drug administration was made either
through a pre-implanted intrathecal catheter or lumbar
puncture. To make the implantation of a intrathecal cath-
eter, a polyethylene (PE-10) catheter that ended at the spinal
L4 segment was intrathecally placed following the technique
previously described [78]. Briefly, rats were anesthetized
under isoflurane (2-3%) and the atlanto-occipital membrane
was exposed by dissection. A PE-10 catheter was carefully
advanced through an opening in the atlanto-occipital mem-
brane to the lumbar enlargement. The wound was then
closed in layers. The animals were allowed to recover for
7 days before behavioral tests were conducted. Following be-
havioral experiments, rats were intrathecally injected with
50 μl of 2% lidocaine. If hind paw paralysis did not ensue,
rats were omitted from the experiment. For drug adminis-
tration through the lumbar puncture, drugs were injected
into the intrathecal space at the L5-L6 lumbar interspace in
rats anesthetized with 2% isoflurane using a 0.5-inch
30-gauge needle connected to a Hamilton syringe as
described previously [79,80].
Behavioral tests
Measurements of mechanical thresholds of hind paw
withdrawal responses
Behavioral tests were conducted in a quiet room with
the room temperature at 22°C [81,82]. To test possible
changes in mechanical sensitivity after a paclitaxel injec-
tion, rats or mice were placed on a wire mesh, loosely
restrained under a plexiglass cage (12 × 20 × 15 cm3)
and allowed to acclimate for at least 30 min for rats and
1.5 h for mice. A series of von Frey monofilaments
(bending force from 0.07 to 26.00 g) were tested in
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for each animal. Each von Frey filament was applied 5 times
to the mid-plantar area of each hind paw from beneath for
about 1 s. The response-frequency [(number of withdrawal
responses of both hind paws/10) × 100%] for each von Frey
filament was determined. Withdrawal response mechanical
threshold was defined as the lowest force filament that
evoked a 50% or greater response-frequency. This value was
later averaged across all animals in each group to yield the
group response threshold [44,82].
Burrowing behavior assessments
Protocols established by others for assessments of bur-
rowing behaviors [33,34] were used. Rats were trained to
burrow based on a previous protocol [33,34]. For base-
line measurements of burrowing activities, individual
rats were placed in an empty cage for 30 min for accli-
mation. A tube (32 cm × 10 cm) filled with 2500 g of
sea gravel was then placed in the cage for 1 hr and bur-
rowing was conducted during the light phase. Burrowing
activities were measured by weighing the remaining
gravel in the tube after each 1 hr burrowing session. The
percentage of gravel displaced was calculated and used
for statistical analysis. The following day after baseline
measurements, rats were randomly assigned to receive
either i.v. injections of taxol or vehicle. Burrowing activ-
ities at different time points after the injection were
determined.
Measurements of paclitaxel concentrations in CSF and
spinal dorsal horn using liquid chromatography tandem
mass spectrometry
At 2, 4 and 24 h after paclitaxel (2 mg/kg) was injected
into rats through the tail vein, CSF was obtained through
intracisternal puncture from rats anesthetized via isoflur-
ane inhalation. The dorsal half of the L4-L5 spinal seg-
ments was collected at the same time point. Paclitaxel
concentrations in CSF and in the spinal dorsal horn were
measured using liquid chromatography tandem mass
spectrometry techniques developed in our lab, which were
described in detail previously [83].
Spinal slice preparations, recording and analysis of
miniature excitatory postsynaptic currents (mEPSCs) from
neurons and glial glutamate transporter currents (GTCs)
from astrocytes in the spinal dorsal horn
Spinal slice preparations
Transverse rat or mouse spinal cord slices (400 μm) of
the L4-L5 segments were prepared as previously de-
scribed [48,49]. Briefly, animals were deeply anesthetized
via isoflurane inhalation. Surgery was performed to expose
and remove the spinal lumbar enlargement segment. The
lumbar spinal cord section was then placed in ice-cold su-
crose artificial cerebrospinal fluid pre-saturated with 95%O2 and 5% CO2. The sucrose aCSF contained 234 mM
sucrose, 3.6 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2,
1.2 mM NaH2PO4, 12.0 mM glucose, and 25.0 mM
NaHCO3. The pia-arachnoid membrane was removed
from the section. The L4-L5 spinal segments was attached
with cyanoacrylate glue to a cutting support, which was then
glued onto the stage of a vibratome (Series 1000, Technical
Products International, St. Louis, MO). Transverse spinal
cord slices were cut in the ice-cold sucrose aCSF and then
pre-incubated in Krebs solution oxygenated with 95% O2
and 5% CO2 at 35°C. The Krebs solution contained:
117.0 mM NaCl, 3.6 mM KCl, 1.2 mM MgCl2, 2.5 mM
CaCl2, 1.2 mM NaH2PO4, 11.0 mM glucose, and 25.0 mM
NaHCO3 at 35°C.
Recordings of mEPSCs
Following pre-incubation, a single slice was placed in
the recording chamber (volume, 1.5 ml), perfused with
Krebs solution at 35°C, and saturated with 95% O2 and
5% CO2. Borosilicate glass recording electrodes (resistance,
3–5 MΩ) were pulled and filled with an internal solution
containing 135 mM potassium-gluconate; 5.0 mM KCl;
2.0 mM MgCl2; 0.5 mM CaCl2; 5.0 mM HEPES; 5.0 mM
EGTA; 5.0 mM ATP-Mg; 0.5 mM Na-GTP; 10 mM
QX-314. Live dorsal horn neurons in the spinal lamina I
and outer lamina II (IIo) were visualized using a micro-
scope system and approached using a three-dimensional
motorized manipulator (Sutter Instrument, Novato, CA,
USA), and whole-cell configurations were established by
applying moderate negative pressure after electrode
contact [84]. Recordings of mEPSCs were made from
neurons receiving monosynaptic input from the primary
afferents using the criteria established previously [81,85].
Miniature EPSCs were recorded in the presence of tetro-
dotoxin (TTX, 1 μM), bicuculline (10 μM), and strychnine
(5 μM) in the external solution to block GABAA, and
glycine receptors at a membrane potential at −70 mV.
Recordings of glutamate transporter currents (GTCs)
GTCs were recorded from male wild-type mice and
TLR4 knockout mice. Other than deletion of the TLR4
gene, TLR4 knockout mice (B10scN-Tlr4lps-del/JthJ) have
a similar genomic background as C57BL/6J mice. The
mouse spinal slice was placed in a recording chamber per-
fused with Krebs solution. Astrocytes in the spinal dorsal
horn laminae I and II were first labeled by the astrocyte
specific dye, sulforhodomine 101 (100 μM) [58], which
was pressure-injected into the spinal slice through a
pipette with a picospritzer [29,58,59]. The identified
astrocyte was patched using borosilicate glass record-
ing electrodes (resistance, 4–6 MΩ) filled with (in mM)
145 potassium-gluconate, 5 NaCl, 1 MgCl2, 0.2 EGTA, 10
HEPES, 2 Mg-ATP and 0.1 Na-GTP (pH 7.3, 290 –
300 mOsm) [51,86]. GTCs were recorded at a holding
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of blockers of GABAA receptor (10 μM bicuculline), glycine
receptor (5 μM strychnine), AMPA/kainate receptors
(10 μM DNQX), NMDA receptor (25 μM D-AP5), and
tetrodotoxin (1 μM) at 35°C [51,56]. GTCs were evoked
by puffing 50 μM L-glutamate onto the recorded astrocyte
through a glass pipette connected to a Picospritzer con-
trolled by a computer.
mEPSCs and GTCs were recorded using Axopatch
700B amplifiers, digitized at 10 kHz, and analyzed
off-line. Access resistance within the range of 10–20 MΩ
was monitored continuously throughout the experiments.
The recording was abandoned when the access resistance
changed more than 20%. The frequency and amplitude of
mEPSCs from 3 min before, during, and after the perfu-
sion of tested drugs were analyzed and averaged using a
peak detection program (MiniAnalysis; Synaptosoft Inc.,
Decatur, GA). Four sweeps of GTCs were averaged and
the mean amplitude and charge transfer of GTCs [87]
were measured. All the drugs were applied through bath-
perfusion unless otherwise indicated.
In vitro measurement of glutamate uptake activity
Synaptosome preparations were prepared from the spinal
tissue. The glutamate uptake activity in the synaptosome
preparation was measured according to previous publica-
tions [51,88]. To investigate the effects of paclitaxel on
glutamate transporter activities, the L4–L5 spinal cord
was exposed by laminectomy and the spinal dura was ex-
cised in rats anesthetized with urethane (1.3–1.5 g/kg, i.p).
The heart rate, breathing, and core temperature of the an-
imals were constantly monitored and maintained within
normal limits [82]. Paclitaxel was applied onto the L4-L5
spinal segments through a piece of cotton soaked with
paclitaxel (concentration: 2 ng/ml) in aCSF at 35°C for
30 min. Rats in the control group receiving vehicles in the
same fashion. Immediately after the treatment, the dorsal
half of the L4-L5 spinal segments was isolated. Synapto-
some preparations were prepared immediately after the
spinal tissue was isolated according to the protocol pub-
lished [50,51]. The spinal tissue was homogenized in ice-
cold buffer solution containing: 0.5 mM EDTA, 0.5 mM
EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.32 M su-
crose, 5 μg/ml pepstatin, 5 μg/ml aprotinin, 20 μg/ml
trypsin inhibitor, 4 μg/ml leupeptin, and 0.01 M phosphate-
buffered saline. The homogenates were centrifuged at
15,000 rpm for 10 min at 4°C, and the supernatant col-
lected. The remaining pellets were resuspended in the same
buffer solution and re-centrifuged at 15,000 rpm for
10 min at 4°C. The two supernatants were combined
and centrifuged again at 13,000 rpm for 10 min at 4°C
to obtain the synaptosomal pellets, which contained
both neuronal and glial glutamate transporters [89].
The synaptosomal pellets were suspended in Locke’sbuffer. The glutamate uptake activity was determined
by incubating the synaptosome preparation with a solu-
tion containing [3H] L-glutamic acid (0.4 μCi/mmol) at
37°C for 5 min. The reaction was terminated by filtering
the synaptosomes through a Whatman GF/B filter pre-
soaked with the same buffer solution. The filter was
then transferred to a vial containing scintillation cocktail
and the radioactivity, which reflects glutamate uptake
activities, in the final samples was measured by a liquid
scintillation counter (Beckman, LS6500).
Western blot experiments
Tissues used for Western blotting were either from in-
tact animals that received i.v. injection of paclitaxel
(2 mg/kg) or vehicle 4 hrs earlier, or intrathecal injection
of paclitaxel (20 ng) or vehicle 1 hr earlier, or spinal
slices that were incubated with paclitaxel (1 ng/ml) or
vehicles for 15 min. Animals were deeply anesthetized
with urethane (1.3–1.5 g/kg, i.p.). The L4-L5 spinal seg-
ments and dorsal root ganglions were exposed by sur-
gery and removed from the rats. Rat spinal slices of the
spinal L4-L5 segments were obtained in the same way as
those for electrophysiological experiments described
above. Spinal slices were incubated with vehicles or pac-
litaxel (1 ng/ml) in aCSF bubbled with 95% O2 and 5%
CO2 at 35°C for 15 min. The dorsal halves of the spinal
cord and dorsal root ganglions were then isolated and
quickly frozen in liquid nitrogen and stored at −80°C for
later use. The frozen tissues were homogenized with a
hand-held pellet pestle in lysis buffer (50 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1%
Deoxycholic acid, 2 mM orthovanadate, 100 mM NaF,
1% Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride,
20 μM leupeptin, 100 IU ml−1 aprotinin) for 0.5 hr at
37°C. Homogenates were then centrifuged at 14000 × g
for 20 min at 4°C and the supernatant were collected. For
measuring protein GLT-1 and GLAST expressions in the
plasma membrane and cytosol, the tissue was fractionated
into cytosolic and membrane fractions with the cyto-
plasmic, nuclear, and membrane compartmental pro-
tein extraction kit (Biochain Institute, Inc.). Protein
concentrations were determined using bicinchoninic
acid (kit from Pierce). Protein samples (40 μg) were
electrophoresed in 10% SDS polyacrylamide gels and trans-
ferred to polyvinylidene difluoride membranes (Millipore,
Bedford, MA). The membranes were blocked with 5% milk
and incubated overnight at 4°C with primary antibodies
against phospho-TLR4/CD284 pTyr674 (1:1000, Thermo
Scientific Pierce Antibodies), TLR4 (1:1000, Abcam,
Cambridge, MA), GLT-1 (1:1000, Millipore, Bedford, MA),
GLAST (1: 2000, Millipore, Bedford, MA) or a monoclonal
mouse anti-β-actin (1:2000, Sigma-Aldrich, St. Louis,
USA) primary antibody as a loading control. The cytosolic
and membrane fractions were checked for specificity by
Table 1 List of DNA primer sequences designed for single-cell RT-PCR
GFAP (371 bp, 218 bp)a CAGAGCGAGCCTATGCTAAA GCCTATGCTAAAGGTTAGGTTGTA NM_001131020
CGTCCAGAGGGAACTAACTAAC AGCACTGAAGTGAAGCAATAGA
GAPDH (367 bp, 313 bp)a AGCCTCGTCCCGTAGACAAAA TGAAGGTCGGTGTGAACGAATT XM_001473623
TTTTGGCTCCACCCCTTCA GCTTTCTCCATGGTGGTGAAGA
a(n, n) indicates product size obtained from outer and inner primers, respectively.
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(1:200; Santa Cruz Biotechnology). Then the blots were
incubated for 1 hr at room temperature with a corre-
sponding HRP-conjugated secondary antibody (1:5000;
Santa Cruz Biotechnology, CA, USA), visualized in ECL
solution (SuperSignal West Pico Chemiluminescent Sub-
strate, Pierce, Rockford, IL, USA) for 1 min, and exposed
onto FluorChem HD2 System. The intensity of immuno-
reactive bands was quantified using ImageJ 1.46 software
(NIH). Results were expressed as the ratio to control
protein.
Single-cell reverse transcription-PCR (RT-PCR)
Single-cell RT-PCR was performed as described previ-
ously [90,91]. Briefly, after electrophysiological record-
ings, the cell which had been labeled with
sulforhodomine 101 for astrocytes [58] was harvested
into a fresh “patch” pipette under fluorescence micros-
copy with a heat-polished tip opening diameter of about
20 μm, which was filled with pipette solution (6 μl) sup-
plemented with 3 U recombinant ribonuclease inhibitor
(RNasin; Promega, Madison,WI). The cell was gently
transferred into a reaction tube (final volume about
10 μl) containing 3.5 μl reaction mix, reverse transcript-
ase buffer (Qiagen), deoxyribonucleotide triphosphates
(dNTPs, concentration: 4 × 250 μM; Applied Biosystems,
Weiterstadt, Germany), random hexanucleotide primer
(50 μM; Roche, Mannheim, Germany), 20 U RNasin (Pro-
mega), and 0.5 μl Sensiscript reverse transcriptase
(Qiagen). The reaction was performed at 37°C (1 hour).
The cDNA of a single cell was amplified using Sensi-
script RT kit (Qiagen). Glial fibrillary acidic protein
were used to identify the harvested cell type. PCR
amplification was performed using the primers shown
in Table 1. All PCR amplifications were performed with
nested primers. The first round of PCR was performed in
50 μl of PCR buffer containing 0.2 mM dNTPs, 0.2 μM
“outer” primers, 5 μl of RT product and 0.2 μl of platinum
TaqDNA polymerase (Invitrogen), 1.5 mM MgCl2. Sam-
ples were heated to 95°C for 5 min. Each cycle consisted
of denaturation at 95°C for 40 s, annealing at 55°C for
40 s, and elongation at 72°C for 40 s. Forty-two cycles
were performed with a programmable thermocycler (Bio-
Rad). The reaction was completed with 7 min of final
elongation. For the second round of amplification, the
reaction buffer (20 μl) contained 0.2 mM dNTPs, 0.2 μM“inner” primers, 5 μl of the first round PCR products,
0.1 μl of platinum TaqDNA polymerase and 1.5 mM
MgCl2. The second PCR condition consisted of denatur-
ation at 95°C for 30 s, annealing at 55°C for 40 s, elong-
ation at 72°C for 40 s for 35 cycles, and the reaction was
completed with 7 min of final elongation and subsequent
cooling to 4°C until analysis. A negative control was ob-
tained from pipettes that did not have cell contents but
were submerged in the bath solution. PCR products were
analyzed on 2% agarose gels.
Materials
Bicuculline, strychnine, tetrodotoxin, 6,7-dinitroquinoxa-
line-2,3-dione (DNQX), L-glutamic acid were obtained
from Sigma (St. Louis, MO, USA). (2S,3S)-3-[3-[4-(Tri-
fluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-
TBOA), D-2-amino-5-phosphonopentanoate (D-AP5) were
obtained from Tocris Bioscience (Minneapolis, MN, USA).
Sulforhodamine 101 and LPS-RS were purchased from Invi-
trogen (San Diego, CA). [3H] L-glutamic acid was obtained
from Perkin Elmer.
Data analysis
All data are presented as the mean ± S.E. The statistical
differences were determined using Student’s t-test (paired
t-test for data obtained within the same group; non-paired
t-test for data obtained from different groups). A P value
less than 0.05 was considered statistically significant.
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